These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 7531601)
1. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Coles RE; Boyle TJ; DiMaio JM; Berend KR; Via DF; Lyerly HK Ann Surg Oncol; 1994 Sep; 1(5):405-10. PubMed ID: 7531601 [TBL] [Abstract][Full Text] [Related]
2. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263 [TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Baiocchi RA; Caligiuri MA Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241 [TBL] [Abstract][Full Text] [Related]
6. The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice. Clinchy B; Vitetta ES J Immunol Methods; 1998 Sep; 218(1-2):141-53. PubMed ID: 9819131 [TBL] [Abstract][Full Text] [Related]
7. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice. Garnier JL; Cooper NR; Cannon MJ Am J Pathol; 1993 Feb; 142(2):353-8. PubMed ID: 7679547 [TBL] [Abstract][Full Text] [Related]
8. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. Boyle TJ; Tamburini M; Berend KR; Kizilbash AM; Borowitz MJ; Lyerly HK Surgery; 1992 Aug; 112(2):378-86. PubMed ID: 1322566 [TBL] [Abstract][Full Text] [Related]
9. Effects of cyclosporine on human B-cell lymphoma development in vivo. Boyle TJ; Coles RE; Kizilbash AM; Lyerly HK Surg Oncol; 1992 Feb; 1(1):79-86. PubMed ID: 1341239 [TBL] [Abstract][Full Text] [Related]
10. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. Purtilo DT; Falk K; Pirruccello SJ; Nakamine H; Kleveland K; Davis JR; Okano M; Taguchi Y; Sanger WG; Beisel KW Int J Cancer; 1991 Feb; 47(4):510-7. PubMed ID: 1847355 [TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. Rowe M; Young LS; Crocker J; Stokes H; Henderson S; Rickinson AB J Exp Med; 1991 Jan; 173(1):147-58. PubMed ID: 1845872 [TBL] [Abstract][Full Text] [Related]
12. Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Abedi MR; Linde A; Christensson B; Mackett M; Hammarström L; Smith CI Int J Cancer; 1997 May; 71(4):624-9. PubMed ID: 9178818 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Ohshima K; Suzumiya J; Sugihara M; Nagafuchi S; Ohga S; Kikuchi M Pathol Int; 1998 Dec; 48(12):934-43. PubMed ID: 9952337 [TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595 [TBL] [Abstract][Full Text] [Related]
15. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Dierksheide JE; Baiocchi RA; Ferketich AK; Roychowdhury S; Pelletier RP; Eisenbeis CF; Caligiuri MA; VanBuskirk AM Blood; 2005 Feb; 105(4):1558-65. PubMed ID: 15498860 [TBL] [Abstract][Full Text] [Related]
16. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Tanner JE; Alfieri C Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802 [TBL] [Abstract][Full Text] [Related]
17. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649 [TBL] [Abstract][Full Text] [Related]
18. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001 [TBL] [Abstract][Full Text] [Related]
19. Administration of rabbit anti-asialo GM1 antiserum facilitates the development of human Epstein-Barr virus-induced lymphoproliferations in xenografted C.B-17 scid/scid mice. Lacerda JF; Ladanyi M; Jagiello C; O'Reilly RJ Transplantation; 1996 Feb; 61(3):492-7. PubMed ID: 8610366 [TBL] [Abstract][Full Text] [Related]
20. Posttransplant Epstein-Barr virus infection is associated with elevated levels of CD19+ B lymphocytes. Morrissey PE; Lorber KM; Marcarelli M; Bia MJ; Kliger AS; Lorber MI Transplantation; 1995 Feb; 59(4):637-40. PubMed ID: 7533350 [No Abstract] [Full Text] [Related] [Next] [New Search]